Torna alla panoramica
SNCTP000004124 | EUCTR2019-004297-26 | BASEC2020-01704

Prophylaktische Behandlung des Ductus arteriosus bei Frühgeborenen durch Paracetamol

Base di dati: BASEC (Importata da 08.05.2024), WHO (Importata da 03.05.2024)
Cambiato: 16 apr 2024, 16:03
Categoria di malattie: Malattia cardiaca coronarica, Malattie neonatali

Descrizione riassuntiva della sperimentazione (Fonte di dati: BASEC)

Die TREOCAPA Studie wird durchgeführt um herauszufinden, ob die präventive Anwendung von Paracetamol bei Frühgeborenen während den ersten fünf Lebenstagen zum Verschluss des Ductus arteriosus sicher und effektiv ist und damit das Risiko für frühgeburtliche Komplikationen vermindern kann.

Malattie studiate(Fonte di dati: BASEC)

Ductus Arteriosus bei Frühgeborenen

Health conditions (Fonte di dati: WHO)

Patent ductus arteriosus;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]

Malattia rara (Fonte di dati: BASEC)

No

Interventi esaminati (p. es. medicamento, terapia, campagna) (Fonte di dati: BASEC)

TREOCAPA ist eine internationale Studie, in der zwei Behandlungsgruppen miteinander verglichen werden: Eine Gruppe mit Paracetamol und eine Gruppe mit Placebo. Die Zuteilung in die jeweiligen Gruppen erfolgt durch das Zufallsprinzip (wie ein Münzwurf). Die Studie wird in mehr als 60 Zentren in 17 europäischen Ländern durchgeführt. Es werden insgesamt 794 Frühgeborene über eine Dauer von 28 Monaten eingeschlossen. Die Studie dauert insgesamt 38 Monate.

Interventions (Fonte di dati: WHO)


Trade Name: Paracetamol
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: acetaminophen
Other descriptive name: PARACETAMOL
Concentration unit: mg/kg milligram(s)/kilogram
Concentration type: up to
Concentration number: 0.75 ml/kg-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use

Criteri per la partecipazione alla sperimentazione (Fonte di dati: BASEC)

Kinder geboren mit 23 - 28 Schwangerschaftswochen
Einschluss innerhalb von 12 Stunden nach Geburt
Einwilligung der Eltern

Criteri di esclusione (Fonte di dati: BASEC)

Schwere Missbildungen
Feto-fetales Transfusionssyndrom bei Zwillingen
Klinische Instabilität, die schnell zum Tod führen kann

Inclusion/Exclusion Criteria (Fonte di dati: WHO)

Gender:
Female: yes
Male: yes

Inclusion criteria:
? Birth between 23-26 W for Phase II, between 23-28 W for Phase III
? Post natal age < 12 hours
? Parental or Legal Authority Consent
? Parents with a social security or health insurance (if applicable)
Are the trial subjects under 18? yes
Number of subjects for this age range: 824
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
? Birth defect / Congenital anomaly
? Twin-to-twin transfusion syndrome
? Suspicion of pulmonary hypoplasia
?Suspicion of hepatic impairment (hemorrhagic syndrome and/or severe hypoglycemia)
? Clinical instability that can lead to rapid death
? Impossibility to start treatment before 12 hours of life
? Parents placed under judicial protection
? Participation in other clinical trial using acetaminophen during the first 5 days of life, indomethacin or ibuprofen during the first 3 days of life or using rescue treatment of PDA not recommended in the TREOCAPA trial

Altri dati sulla sperimentazione nel registro primario dell’OMS

https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-004297-26

Altri dati sulla sperimentazione dalla banca dati dell’OMS (ICTRP)

https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2019-004297-26
Altre informazioni sulla sperimentazione

Data di registrazione della sperimentazione

20 lug 2020

Inserimento del primo partecipante

21 dic 2020

Stato di reclutamento

Not Recruiting

Titolo scientifico (Fonte di dati: WHO)

Prophylactic treatment of the ductus arteriosus in preterm infants by acetaminophen - TREOCAPA

Tipo di sperimentazione (Fonte di dati: WHO)

Interventional clinical trial of medicinal product

Disegno della sperimentazione (Fonte di dati: WHO)

Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 2

Fase (Fonte di dati: WHO)

Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): yesTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no

Punti finali primari (Fonte di dati: WHO)

Main Objective: Primary objectives :
Phase II: The objective of Phase II is to define the minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7 in preterm infants of 23-26 weeks of gestation

Phase III: The primary objective is an increase in surviving without severe morbidity at 36 weeks of post menstrual age (or at discharge if it occurs before) from 50% (placebo group) to 60% in group receiving a prophylactic treatment by acetaminophen during the first 5 days of life.;Secondary Objective: Secondary objectives :
Phase II:
? Tolerance of acetaminophen at each dose
? Pharmacokinetics of acetaminophen and evaluation of the concentration-response curve (i.e., acetaminophen exposure vs. time to close the ductus arteriosus or decrease the size of ductus).
? To evaluate the relationship between acetaminophen concentration and toxicity occurrence.

Phase III:
? Early prophylactic treatment by acetaminophen decreases pain score and opiate consumption during the first 5 days of life.
? Early prophylactic treatment by acetaminophen reduces the number of back-up treatment of PDA (NSAIDs, surgery, trans-catheter procedure)
? Early prophylactic treatment by acetaminophen reduces catecholamines, opioid and parenteral nutrition requirements
? Pharmacokinetics of acetaminophen (in 50 preterms).;Primary end point(s): Primary endpoint of phase II is the closure of Ductus Arteriosus (DA) assessed by echocardiography during the first 7 days of life, defined as DA closed at two consecutive echocardiographies or if the DA is closed at echocardiography of Day 7
Primary endpoint of phase III is the survival without severe morbidity at 36 weeks of post menstrual age or at first discharge home, whichever comes first. The severe morbidities include bronchopulmonary dysplasia (BPD Grade 3 according to NIH consensus), necrotizing enterocolitis (NEC) of Bell's stage II or III, intraventricular hemorrhage (IVH) grade III-IV or cystic leukomalacia observed at any time up to 36 weeks of post menstrual age.;Timepoint(s) of evaluation of this end point: Primary endpoint of phase II will be evaluate at day 7.

Primary endpoint of phase III is evaluate at 36 weeks of post menstrual age or at first discharge home.

Punti finali secondari (Fonte di dati: WHO)

Secondary end point(s): Main secondary endpoints of phase II are tolerance of acetaminophen. We will investigate:
(1) Acetaminophen serum levels
(2) Serum ALAT & ASAT
(3) Prospective clinical monitoring
(4) Adverse effects and concomitant drug exposures


Main secondary endpoints of phase III are:
(1) Number of rescue treatment to close ductus by non steroid antiinflamatory drugs (NSAIDs) or by surgery or by transcatheter.
(2) Diastolic systemic arterial pressure during the first week
(3) Early and all Pulmonary hemorrhage
(4) Cathecholamines, and opiate consumption during the first week of life
(5) Volume of enteral nutrition during the first week of life
(6) Interaction between parent involvement during the first week of life and medical care;Timepoint(s) of evaluation of this end point: At 36 weeks of post menstrual age or at first discharge home

Contatto per informazioni (Fonte di dati: WHO)

Innovative Medicines Initiative 2 (H2020 programme)

Risultati della sperimentazione (Fonte di dati: WHO)

Sintesi dei risultati

Prophylactic treatment of the ductus arteriosus in preterm infants by acetaminophen

Collegamento ai risultati nel registro primario

ancora nessuna informazione disponibile

Informazioni sulla disponibilità dei dati dei singoli partecipanti

ancora nessuna informazione disponibile

Siti di esecuzione della sperimentazione

Siti di esecuzione in Svizzera (Fonte di dati: BASEC)

Ginevra, Losanna, Zurigo

Paesi di esecuzione (Fonte di dati: WHO)

Austria, Belgium, Denmark, Estonia, Finland, France, Greece, Hungary, Ireland, Italy, Norway, Poland, Portugal, Spain, Sweden, Switzerland, United Kingdom

Contatto per maggiori informazioni sulla sperimentazione

Dati della persona di contatto in Svizzera (Fonte di dati: BASEC)

Dr. med. Christoph Rüegger
0041 43 253 98 10
christoph.rueegger@usz.ch

Contatto per informazioni generali (Fonte di dati: WHO)

Sandrine COUFFIN-CADIERGUES
8 rue de la Croix jarry
Inserm
33144 23 64 16
rqrc.siege@inserm.fr

Contatto per informazioni scientifiche (Fonte di dati: WHO)

Sandrine COUFFIN-CADIERGUES
8 rue de la Croix jarry
Inserm
33144 23 64 16
rqrc.siege@inserm.fr

Autorizzazione da parte della commissione d’etica (Fonte di dati: BASEC)

Nome della commissione d’etica che rilascia l’autorizzazione (nel caso di studi multicentrici solo la commissione direttiva)

Kantonale Ethikkommission Zürich

Data di autorizzazione da parte della commissione d’etica

17.09.2020

Altri numeri di identificazione delle sperimentazioni

Numero di identificazione della sperimentazione della commissione d’etica (BASEC-ID) (Fonte di dati: BASEC)

2020-01704

Secondary ID (Fonte di dati: WHO)

C19-29
2019-004297-26-FR
Torna alla panoramica